fection varies so widely that one may encounter fatal infections by staphylococci that are ordinarily nonpathogenic and trivial lesions caused by pathogenic staphylococci. Nevertheless division of staphylococci into these 2 groups is worthwhile, for even when infection is incited by a "lnonipathogenic'" staphylococcus, the clinical and pathologic features of the resultant disease differ significantly in most cases from that caused by a typically pathogenic strain.
Staphylococei isolated from lesions that stamp them as being unequivocally pathogenic for man are characterized usually by golden or orange pigment and the ability to produce in vitro a remarkable array of extracellular toxic or enzymic substances; these include coagulase, at least 3 hemolysins, a leukoeidin active against human leukocytes, enterotoxin, hyaluronidase, fibriniolysinl, phosphatase, lipase, enzymes mediating the fermentation of mannitol, as well as other compounds. In general the more virulent staphylococci, as assayed in mice, produce a greater number of extracellular antigenic, and presumably toxic, subtanees.
The most conveniently determined and reliable evidence of pathogenicity is the production of coagulase.* This substance, in the presence of a co-factor found in human or rabbit plasma, induces the clotting of fibrinogen. It may be readily detected by inoculating a culture of the microorganism into a tube of diluted human or rabbit plasma. Coagulasepositive strains yield a clot usually within 3 hours, occasionally as late as 18 to 24 hours. A rapid slide test has been proposed for this purpose but it may not detect the same entity as the tube test. 3 The production of alpha lysin, a hemolysin relatively specific for rabbit erythrocytes, correlates very well with clinical evidence of pathogenicity. In the opinion of some investigators it is a better index of pathogenicity than coagulase production. However staphylococci produce at least 2 other hemolysins (beta and delta lysins) with maximum lytic activity against erythrocytes of other species and poorer correlation with pathogenicity for man. Specific tests for alpha-lysin production are not usually performed in clinical bacteriology laboratories. Accordingly, the common laboratory report of a " hemolytic " staphylococcus without further qualification is ambiguous, and may be misleading when taken as an index of pathogenicity.
Although more than 90 per cent of pathogenic staphylococci are yellow in color, gray or white strains of staphyloceci cannot be regularly dismissed as nonpathogenic without the danger of serious error. Occasionally such strains may produce coagulase and alpha lysin and be responsible for outbreaks of highly invasive infection. Furthermore, production of yellow pigment is not a very stable property of staphylococci, as is demonstrated by the ease with which albus variants, which still produce coagulase and alpha lysin, are obtained in vitro from typical pathogenic aureus strains. By the same token aureus strains should not be regarded ipso facto as being pathogenic.
Bacteriophage Typing
Although the toxic products of the staphylococcus are useful in defining pathogenic and nonpathogenic species, they do not provide a basis for subclassification of strains within either species. The advantages of a sharper characterization have been realized in recent years through the development of bacteriophage typing.4 Coagulase-positive staphylococci may be classified into 4 broad groups, I to IV, according to their susceptibility to lysis by a battery of stock bacteriophages. More specifically, the bacteriophage type of a given strain may be described by the numerical designations of the bacteriophages to which it is susceptible (e.g., 42B/80/81/52). This procedure has yielded results of great importance. Significant (1) ACTH and glueocorticoid hormones.
(2) Hematopoletic toxins, e.g., 6-mercaptopurine, folic acid antagonists, nitrogen mustard.
(3) Ionizing radiation.
arteriovenous fistulas, bacterial endocarditis occurs frequently upon normal valves without the deliberate injection of bacteria.14 Also, by prior exposure to the cardiovascular stress of living under conditions simulating high altitude, rats may be rendered highly susceptible to the development of endocarditis following intravenous injection of bacteria. 15 The clinical setting in which staphylococcal endocarditis occurs is very variable. In some patients with acquired valvular or congenital heart disease, but otherwise in good health, endocarditis may begin without any obvious primary source of infection and without contact with hospital strains of staphylococci. Usually the diagnosis is not difficult and the likelihood of success in treatment may be rel-atively good. In other patients, more often without obvious cardiac disease, but with some of the predisposing factors cited earlier, endocarditis may make its appearance secondary to staphylococcal infection at other sites. The illness is often contracted in the hospital environment and the attendant problems of antibiotic resistant strains of staphylococei and underlying disease make treatment more difficult and recovery less likely. In a third group of patients endoearditis may be only one of multiple metastatic foci in severe bacteremic staphylococcal infection and indeed may be an incidental and relatively unimportant teminal event. Accordingly, the term staphylococcal endoearditis does not define a uniform clinical entity. Questions of prognosis, prevention, and treatment cannot be treated meaningfully without reference to the clinical substrate in which the disease has occurred.
Staphylococeic endocarditis is usually a rapidly progressive typically acute endocarditis, but milder, more prolonged illnesses similar to subacute bacterial endocarditis are also seen usually with strains reported as Staphylococcus albus which may be inferred to be coagulase-negative in most cases. Infection by coagulase-negative strains almost always takes places on an existing cardiac deformity, whereas 40 per cent of cases of coagulase-positive staphyloeoccal endocarditis begin on a previously normal valve. An additional difference is that infarets resulting from embolism in coagulase-negative staphylocoecal endocarditis are usually bland in contrast to the septic infarets characteristic of endoearditis caused by coagulase-positive organisms.
The clinical features of staphylococeal endocarditis are well known and require no elaboration.16-18 They include fever, often with chills and evidence of severe toxicity. Signs of cerebral damage are common, including stupor, coma, nuchal rigidity, and hemiparesis. Petechiae, skin rashes, splenomegaly, and obvious peripheral embolization are relatively uncommon in patients seen reasonably early in their illness. Murmurs adequate to suggest the presence of heart disease, most often rheumatic valvular disease, may be heard in from 50 to 75 per cent of eases. Marked change in the character of a murmur or the appearance of a new murmur is a most helpful but relatively infrequent sign. Laboratory findings usually include a normocytic, normochromic anemia, slight to moderate polymorphonuclear leukocytosis, albuminuria, and microscopic hematuria.
Blood culture is the essential test to establish the diagnosis. Fortunately the blood culture is almost invariably positive in untreated staphylococcal endocarditis. However to which the staphylococcus should be sensi-COHEN tive. These agents may be administered initially in doses as high as 0.5 to 1 Gm. intravenously every 6 hours and reduced to half that amount after 3 to 5 days. One million units of penicillin G contain 1.7 mEq. of sodium or potassium. Appropriate amounts of the desired salt should be given where control of salt intake is important.
Vancomycin appears to be the agent of choice for treatment of penicillin-resistant staphylococcal endocarditis, on the basis of admittedly scanty clinical data. This antibiotic is effective against virtually all staphylococci. The bactericidal concentration is not more than twice the bacteriostatic level and readily attained in therapy without significant toxicity. Resistant strains have not been developed by treatment in man nor are they readily obtained in vitro. Toxic manifestations appear to be restricted to occasional pyrogenic reactions, thrombophlebitis, and, rarely, impairment of hearing when high dosage or impaired renal function permit the accumulation of undesirably high blood levels. Geraci and his colleagues have reported bacteriologic cure with vancomycin in 5 of 6 cases of staphylococcal endocarditis.27 Recommended dosage is 0.5 Gm. intravenously diluted with saline or glucose solution every 4 to 6 hours for 4 to 6 weeks.
Kanamycin, one of the newer antistaphylococcal antibiotics, is related chemically to neomycin, with which it exhibits reciprocal crosssensitivity and resistance. Bactericidal concentrations are readily attained in the blood after intramuscular injection. Clinical reports are inadequate to evaluate its effectiveness in staphylococcal endocarditis. Careful clinical trial is warranted in staphylococcal infections of the heart in which penicillin or vancomycin is either contraindicated or ineffective. Kanamycin is significantly toxic to the kidneys and the auditory nerve. Damage to these organs may be encountered even on therapeutic dosage, particularly if it is prolonged or if renal disease causes the accumulation of high blood levels. Recommended dosage is 0.5 Gm. intramuscularly 4 to 6 times daily. 30 Similarly the place of another new antibiotic, ristocetin is still undetermined. It has been reported to have been effective in many staphylococcal infections, including a few cases of endocarditis. However some investigators have found it to be ineffective in some cases of severe systemic staphylococcal infection even without endocarditis.A Concentrations that would be bactericidal for staphylococci are higher than can be attained in serum. Marked, but reversible leukopenia and, to a lesser extent, thrombocytopenia have accompanied its use in a variable proportion of patients. Additional evidence is necessary before it can be recommeded for use in staphylococcal endocarditis.
The bacteriostatic antibiotics erythromycin, novobiocin, the tetracyclines, chloramphenicol, and the relatively toxic agents bacitracin and neomyein, for the most part given in various combinations, are not notably effective in staphylococcal endocarditis although occasional cures have been reported. Directions for their use in staphylococcal endocarditis are available and will not be repeated here.'9 It should be noted that recent observations bring into question the advisability of using the common combination of 'erythromycin and chloramphenicol. Barber has reported, in confirmation of older observations, that staphylococci resistant to erythromycin may concomitantly show partial resistance to chloramphenicol. She recommends erythromycin plus novobiocin as a more desirable combination. 32 If Probably more than 50 per cent of cases of staphylococcal endocarditis are the result of infections acquired in hospitals. Insofar as the rate of hospital-acquired staphylococcal infection can be reduced, the incidence of endocarditis should also decline. Recommendations to this end are numerous and entail many administrative complexities.34 Among the simpler steps that may be of value are (1) rigorous aseptic technic in surgery, (2) restriction of intravenous catheterization and "cut downs" to the minimum, coupled with careful protection of the site from infection, (3) protection of the inordinately susceptible group of patients by isolation from the general hospital population, (4) meticulous, bacteriologically controlled hospital housekeeping.
Gould has suggested that the high prevalence of penicillin-resistant staphylococci in hospitals is due to the continuous fall-out of penicillin aerosol derived from the widespread use of the antibiotic. 35 If this hypothesis is correct, limitation of contamination of the environment by antibiotics may be an additional step in prevention.
The benefit to be expected from prophylaxis by antibiotics against staphylococcal infection is open to question in view of the high proportion of antibiotic-resistant strains. Where it has been possible to arrange a controlled test of more or less blanket prophylaxis, the results have not disclosed significant benefit. It is possible, however, that prophylaxis against bacterial endocarditis may depend upon the ability to eradicate a small number of infectious organisms from the blood stream or the endocardial surface and hence may be specially feasible. 
